|
|
Research progress of leukotrienes associated with the atherosclerosis |
HUANG Jiaxin1 TIAN Ji1 NI Wei2 DU Wenwen3 HUANG Rongzeng1 SONG Chengwu1 XIE Yun1 JIN Shuna4 |
1.College of Pharmacy, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430065, China;
2.Department of Laboratory, Hubei Provincial Hospital of TCM, Hubei Province, Wuhan 430060, China;
3.Department of Pharmacy, Jiaozuo People′s Hospital, He′nan Province, Jiaozuo 454000, China;
4.School of Public Health, Huazhong University of Science and Technology, Hubei Province, Wuhan 430030, China |
|
|
Abstract Lukotrienes (LTs) are inflammatory mediators of eicosanoids in leukocytes, which are formed by arachidonic acid and eicosapentaenoic acid through the oxidation of arachidonic acid 5-lipoxygenase. This article gives a brief overview of physical and chemical properties of LTs, then details the significance of clinical monitoring between LTs and atherosclerosis through the lipoxygenase pathway metabolic processes and their products. Besides, the associations between LTs and atherosclerosis in the reported animal and human studies are assessed, which can provide suggestion for screening LTs-based disease biomarkers and be as the available reference of their new clinically targeted treatment options.
|
|
|
|
|
[1] Feldberg W,Holden HF,Kellaway CH. The formation of lysocithin and of a muscle-stimulating substance by snake venoms [J]. J Physiol,1938,94(2):232-248.
[2] Samuelsson B,Borgeat P,Hammarstrom S,et al. Introduction of a nomenclature: leukotrienes [J]. Prostaglandins,1979,17(6):785-787.
[3] Bochenek G,Stachura T,Szafraniec K,et al. Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma [J]. J Allergy Clin Immunol Pract,2018,6(2):528-535.
[4] Gabri■ D,Petru?觢ev NH,Gjorgievska E,et al. Circulatory leukotriene changes during bone healing following Er:YAG laser and piezosurgery osteotomies-an animal study [J]. Clinical Oral Implants Research,2017,28(S14):115.
[5] Knights AJ,Vohralik EJ,Hoehn KL,et al. Defining Eosinophil Function in Adiposity and Weight Loss [J]. Bioessays,2018, 40(10):e1800098.
[6] Zhou J,Chen L,Liu Z,et al. Changes in erythrocyte polyunsaturated fatty acids and plasma eicosanoids level in patients with asthma [J]. Lipids Health Dis,2018,17(1):206.
[7] Khajeh M,Rahbarghazi R,Nouri M,et al. Potential role of polyunsaturated fatty acids,with particular regard to the signaling pathways of arachidonic acid and its derivatives in the process of maturation of the oocytes:Contemporary review [J]. Biomed Pharmacother,2017,94:458-467.
[8] Yanes DA,Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis:The prostaglandin/leukotriene pathway [J]. J Am Acad Dermatol,2018,78(3 Suppl 1):S71-S75.
[9] Gammelmark A,Lundbye-Christensen S,Tjonneland A,et al. Interactions between 5-Lipoxygenase Polymorphisms and Adipose Tissue Contents of Arachidonic and Eicosapentaenoic Acids Do Not Affect Risk of Myocardial Infarction in Middle-Aged Men and Women in a Danish Case-Cohort Study [J]. J Nutr,2017,147(7):1340-1347.
[10] Vo TTL,Jang WJ,Jeong CH. Leukotriene A4 hydrolase:an emerging target of natural products for cancer chemoprevention and chemotherapy [J]. Ann N Y Acad Sci,2018,1431(1):3-13.
[11] Numao S,Hasler F,Laguerre C,et al. Feasibility and physiological relevance of designing highly potent amino-peptidase-sparing leukotriene A4 hydrolase inhibitors [J]. Sci Rep,2017,7(1):13591.
[12] Cheung DS,Sigua JA,Simpson PM,et al. Cysteinyl leuk-otriene receptor 1 expression identifies a subset of neutrophils during the antiviral response that contributes to postviral atopic airway disease [J]. J Allergy Clin Immunol,2018,142(4):1206-1217.
[13] Bankova LG,Boyce JA. A new spin on mast cells and cysteinyl leukotrienes:Leukotriene E4 activates mast cells in vivo [J]. J Allergy Clin Immunol,2018,142(4):1056-1057.
[14] Zheng C,Shi X. Cysteinyl leukotriene receptor 1(cysLT1R)regulates osteoclast differentiation and bone resorption [J]. Artif Cells Nanomed Biotechnol,2018,46(sup3):S64-S70.
[15] Gelfand EW. Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma [J]. Semin Immunol,2017,33:44-51.
[16] Song M,Xu S,Zhong A,et al. Crosstalk between macrophage and T cell in atherosclerosis: Potential therapeutic targets for cardiovascular diseases [J]. Clin Immunol,2019, 202:11-17.
[17] Werz O,Gerstmeier J,Libreros S,et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity [J]. Nat Commun,2018,9(1):59.
[18] Zolot J. Updated Recommendations for Preventing CVD with Statins [J]. Am J Nurs,2017,117(2):15.
[19] Lai XF,Qin HD,Guo LL,et al. Hypercholesterolemia increases the production of leukotriene B4 in neutrophils by enhancing the nuclear localization of 5-lipoxygenase [J]. Cell Physiol Biochem,2014,34(5):1723-1732.
[20] Li J,Bruns AF,Hou B,et al. Orai3 Surface Accumulation and Calcium Entry Evoked by Vascular Endothelial Growth Factor [J]. Arterioscler Thromb Vasc Biol,2015, 35(9):1987-1994.
[21] Mawhin MA,Tilly P,Zirka G,et al. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia [J]. Cardiovasc Res,2018,114(12):1656-1666.
[22] Gur ZT,Caliskan B,Banoglu E. Drug discovery approaches targeting 5-lipoxygenase-activating protein(FLAP)for inhibition of cellular leukotriene biosynthesis [J]. Eur J Med Chem,2018,153:34-48.
[23] Merhi M,Demirdjian S,Hariri E,et al. Impact of inflammation,gene variants,and cigarette smoking on coronary artery disease risk [J]. Inflamm Res,2015,64(6):415-422.
[24] Matsumoto S,Ibrahim R,Gregoire JC,et al. Effect of treatment with 5-lipoxygenase inhibitor VIA-2291(atreleuton)on coronary plaque progression:a serial CT angiography study [J]. Clin Cardiol,2017,40(4):210-215.
[25] Nadarajan K,Balaram P,Khoo BY. MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARalpha/gamma,FGF4 and 5LOX [J]. Cytotechnology,2016,68(5):1771-1787.
[26] Tsuda S,Shinohara M,Oshita T,et al. Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B4 pathway by high-density lipoprotein in macrophages [J]. Sci Rep,2017,7(1):12989.
[27] Pleskovic A,Letonja MS,Vujkovac AC,et al. Matrix met-alloproteinase-3 gene polymorphism(rs3025058)affects markers atherosclerosis in type 2 diabetes mellitus [J]. Vasa,2017,46(5):363-369.
[28] Zovko A,Yektaei-Karin E,Salamon D,et al. Montelukast,a cysteinyl leukotriene receptor antagonist,inhibits the growth of chronic myeloid leukemia cells through apoptosis [J]. Oncol Rep,2018,40(2):902-908.
[29] Yashaswini PS,Sadashivaiah B,Ramaprasad TR,et al. In vivo modulation of LPS induced leukotrienes generation and oxidative stress by sesame lignans [J]. J Nutr Biochem,2017,41:151-157.
[30] Tam FWK,Ong ACM. Renal monocyte chemoattractant protein-1:an emerging universal biomarker and therapeutic target for kidney diseases? [J]. Nephrol Dial Transplant,2019:410-411. [Epub ahead of print]
[31] Bianconi V,Sahebkar A,Atkin SL,et al. The regulation and importance of monocyte chemoattractant protein-1 [J]. Curr Opin Hematol,2018,25(1):44-51.
[32] Colazzo F,Gelosa P,Tremoli E,et al. Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases [J]. Mediators Inflamm,2017, 2017:2432958.
[33] Gautier-Veyret E,Back M,Arnaud C,et al. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome [J]. Pharmacol Res,2018,134:311-319.
[34] Ding M,He SJ,Yang J. MCP-1/CCL2 Mediated by Autocrine Loop of PDGF-BB Promotes Invasion of Lung Cancer Cell by Recruitment of Macrophages Via CCL2-CCR2 Axis [J]. J Interferon Cytokine Res,2019,39(4):224-232.
[35] Said MM,Bosland MC. The anti-inflammatory effect of montelukast,a cysteinyl leukotriene receptor-1 antagonist,against estradiol-induced nonbacterial inflammation in the rat prostate [J]. Naunyn Schmiedebergs Arch Pharmacol,2017,390(2):197-205.
[36] Di X,Tang X,Di X. Montelukast inhibits oxidized low-density lipoproteins(ox-LDL)induced vascular endothelial attachment: An implication for the treatment of atherosclerosis [J]. Biochem Biophys Res Commun,2017, 486(1):58-62. |
|
|
|